ReviewWorld journal of surgical oncology2025
Mapping the landscape of ovarian metastases of gastric cancer: insights, trends, and emerging perspectives.
Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-site sequencing supports dual-track evolution and identifies candidate metastasis-associated factors in gastric cancer ovarian metastasis.Clinical and translational medicine · 2026Article
- Diagnostic significance of cancer antigen 125/carcinoembryonic antigen ratio combined with IOTA-ADNEX model in discriminating between primary ovarian cancer and ovarian metastases.Quantitative imaging in medicine and surgery · 2026Article
- Molecular characteristics and metastatic mechanism of patients diagnosed with Krukenberg tumor from gastric cancer.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGastric cancer (GC) has poor prognosis due to distant metastasis with ovarian metastasis (OM) occurring in 5-10% of female patients and survival limited to 7-14 months. No standard treatment exists. This review analyzes global research and trends in OM management.
methodsPublications on OM in GC (1991-2024) were retrieved from the Web of Science Core Collection. Bibliometric analysis of 324 articles was performed using CiteSpace and VOSviewer.
resultsThree main themes emerged: (1) diagnosis and pathology characteristics of OM, (2) treatment and management, and (3) clinical features in special populations, such as pregnancy.
conclusionResearch hotspots include multidisciplinary treatment (MDT), diagnostic tumor markers (e.g., CA125, CA19-9, and carcinoembryonic antigen (CEA)), imaging (e.g., MRI, ultrasound), and novel approaches such as immunotherapy and targeted therapy (Microsatellite Instability-High (MSI - H), Tumor Mutational Burden-High (TMB - H). Future directions call for multicenter clinical trials and interdisciplinary collaboration to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.